An estimate of the benefit-cost impact of the FDA guidance on data monitoring committees

Therapeutic Innovation and Regulatory Science

Volumn 49, Issue 5, 2015, Pages 698-705

  Seltzer, Jonathan ^a,b  

^a ACI Clinical   (United States)

^b Medical Research   (United States)

Author keywords

Benefit; Cost; Data monitoring committees; FDA guidance; Impact

Indexed keywords

ARTICLE; CLINICAL TRIAL (TOPIC); COST BENEFIT ANALYSIS; EARLY TERMINATION OF CLINICAL TRIAL; ECONOMIC ASPECT; FOOD AND DRUG ADMINISTRATION; HUMAN; MEDICAL LITERATURE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROFESSIONAL STANDARD; PUBLICATION;

EID: 84960417033     PISSN: 21684790     EISSN: 21684804     Source Type: Journal    
DOI: 10.1177/2168479015573586     Document Type: Article

References (15)

1. US Food and Drug Administration. Guidance and regulation. http://www.fda.gov/Food/GuidanceRegulation. Accessed December 9, 2014.
2. Hirshberg B, Katz A. Cardiovascular outcome studies with novel antidiabetes agents: scientific and operational considerations. Diabetes Care. 2013;36(suppl 2):S253-S258.
3. US Food and Drug Administration. Economic impact analyses of FDA regulations. http://www.fda.gov/AboutFDA/ReportsManualsForms/Reports/EconomicAnalyses/. Accessed December 9, 2014.
4. Bouvy J, Koopmanschap M, Shah R, Schellekens H. The cost-effectiveness of drug regulation: the example of thorough QT/QTc studies. Clin Pharmacol Ther. 2012;91(2):281-288.
5. Pasquali S, Lam W, Chiswell K, Kemper A, Li J. Status of the pediatric clinical trials enterprise: an analysis of the US Clinical-Trials.gov Registry. Pediatrics. 2012;130(5):e1269-e1277.
6. US Food and Drug Administration. The establishment and operation of clinical trial data monitoring committees for clinical trial sponsors. http://www.fda.gov/regulatoryinformation/guidances/ucm127069.htm. Published March 2006. Accessed December 9, 2014.
7. Department of Health and Human Services. Institutional review boards: a time for reform. https://oig.hhs.gov/oei/reports/oei-01-97-00193.pdf. Accessed December 9, 2014.
8. Wadman M. FDA says study overestimated non-compliance with data-reporting laws. Nature. May 1, 2012.
9. US National Institutes of Health. ClinicalTrials.gov. Histories, policies, and laws. http://ClinicalTrials.gov/ct2/about-site/history. Accessed November 2015.
10. DeAngelis C, Drazen J, Frizelle F, et al. Clinical trial registration: a statement from the International Committee of Medical Journal Editors. JAMA. 2004;292(11):1363-1364.
11. Sydes M, Altman D, Babikera A, Parmar M, Spiegelhalter D. DAMOCLES Group. Reported use of data monitoring committees in the main published reports of randomized controlled trials: a cross-sectional study. Clin Trials. 2004;1(1): 48-59.
12. Berndt E, Cockburn I. Price indexes for clinical trial research: a feasibility study. http://www.bls.gov/opub/mlr/2014/article/pdf/price-indexes-for-clinical-trial-research-a-feasibility-study.pdf. Accessed December 9, 2014.
13. Bussom D, Winter L. Data monitoring committees: implementation and sourcing model options. http://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/OnlineþExtras/Data-Monitoring-Committees-Implementation-and-Sour/ArticleStandard/Article/detail/835338?contextCategoryId¼47497. Published 2014. Accessed December 9, 2014.
14. Califf RM, Zarin DA, Kramer JM, Sherman RE, Aberle LH, Tas- neem A. Characteristics of clinical trials registered in Clinical-Trials.gov, 2007-2010. JAMA. 2012;307:1838-1847.
15. Thomson Reuters. Science citation reports 2010 (impact factor) by Journal Citation Reports. http://www.rcmishra.com/research-tools/impact-factor-2010-journal-citation-reports-by-thomsonreutors. Accessed November 2015.